Abstract
Palbociclib is an orally available CDK4/6 inhibitor. In humans, palbociclib undergoes metabolism mediated primarily by CYP3A and SULT2A1, and it is al......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
